IMPACT OF OBESITY ON SUSTAINED VIROLOGIC RESPONSE TO SOFOSBUVIR BASED REGIMENS IN THE EGYPTIAN CHRONIC HEPATITIS C PATIENTS
ALLAM, A., ANWAR, A., NASSER, H., KABIEL, W., FARID, A. (2019). IMPACT OF OBESITY ON SUSTAINED VIROLOGIC RESPONSE TO SOFOSBUVIR BASED REGIMENS IN THE EGYPTIAN CHRONIC HEPATITIS C PATIENTS. EKB Journal Management System, 49(3), 699-706. doi: 10.21608/jesp.2019.68077
AHMED SAMIR ALLAM; AYMAN GAMIL ANWAR; HAYTHAM MOHAMED NASSER; WALAA AHMED YOUSRY KABIEL; AMIR M. FARID. "IMPACT OF OBESITY ON SUSTAINED VIROLOGIC RESPONSE TO SOFOSBUVIR BASED REGIMENS IN THE EGYPTIAN CHRONIC HEPATITIS C PATIENTS". EKB Journal Management System, 49, 3, 2019, 699-706. doi: 10.21608/jesp.2019.68077
ALLAM, A., ANWAR, A., NASSER, H., KABIEL, W., FARID, A. (2019). 'IMPACT OF OBESITY ON SUSTAINED VIROLOGIC RESPONSE TO SOFOSBUVIR BASED REGIMENS IN THE EGYPTIAN CHRONIC HEPATITIS C PATIENTS', EKB Journal Management System, 49(3), pp. 699-706. doi: 10.21608/jesp.2019.68077
ALLAM, A., ANWAR, A., NASSER, H., KABIEL, W., FARID, A. IMPACT OF OBESITY ON SUSTAINED VIROLOGIC RESPONSE TO SOFOSBUVIR BASED REGIMENS IN THE EGYPTIAN CHRONIC HEPATITIS C PATIENTS. EKB Journal Management System, 2019; 49(3): 699-706. doi: 10.21608/jesp.2019.68077

IMPACT OF OBESITY ON SUSTAINED VIROLOGIC RESPONSE TO SOFOSBUVIR BASED REGIMENS IN THE EGYPTIAN CHRONIC HEPATITIS C PATIENTS

Journal of the Egyptian Society of Parasitology
Article 24, Volume 49, Issue 3, December 2019, Page 699-706  XML PDF (172.96 K)
Document Type: Original Article
DOI: 10.21608/jesp.2019.68077
View on SCiNiTO View on SCiNiTO
Authors
AHMED SAMIR ALLAM1; AYMAN GAMIL ANWAR1; HAYTHAM MOHAMED NASSER2; WALAA AHMED YOUSRY KABIEL3; AMIR M. FARID4
1Departments of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
2Departments of Radiology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
3Departments of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
4Departments of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Abstract
Hepatitis C virus is one of the flaviviruses that can cause both acute and chronic hepatitis. Chronic HCV infection often follows a progressive course over years that could result in cirrhosis, hepatocellular carcinoma, and possible liver transplantation. Identifying modifiable risk factors that add to progression of the disease in HCV patients aids in choosing treatment approaches and overall disease management. Hepatic fibrosis may occur as a result of obesity, host, virus-mediated factors and hepatic steatosis. Nonetheless, the role of overweight and obesity on hepatitis C progression remains debatable. Nowadays, Direct Acting Antiviral therapy is the cornerstone of treatment of chronic hepatitis C virus infection aiming to eradicate HCV RNA, which is predicted by reaching sustained virologic response (SVR). This prospective observational cross sectional study assessed the impact of obesity on the SVR to Sofosbuvir based therapy in patients with chronic HCV infection. The study included 188 chronic hepatitis C patients eligible for antiviral therapy according to the Egyptian guidelines issued by the National Committee for Control of Viral Hepatitis. G1: 93 obese patients
with BMI ≥30 kg/m2 & G2: 95 non obese patients with BMI < 30kg/m2. Each group was subdivided into 3 subgroups; GA received Sofosbuvir & Daclatasvir, GB received Sofosbuvir & Simeprevir while GC received Sofosbuvir & Ledipasvir.
The results showed that overall SVR was 96.7% in G1 and 95.7% in G2. There was no association found between stage of fibrosis and SVR, and no significant association reached between obesity and sustained virologic response (SVR) to Sofosbuvir based regimens.
Keywords
Hepatitis C virus; Sofosbuvir; HCV/RNA; Sustained virologic response; Obesity
Statistics
Article View: 222
PDF Download: 237